Today, the National Growth Fund announced that PharmaNL has met the conditions to convert the conditional allocation of €78.8 million into a definitive grant.
“We at PharmaNL are delighted with this news. Together with stakeholders, we can now begin implementing the ambitions of PharmaNL,” said Brigitte Drees, Director of Pivot Park.
Click here to view the official announcement from the Dutch government.
PharmaNL is a national public-private consortium comprising Leiden University Medical Center, Leiden University, Campus Groningen, and Pivot Park, working closely with FAST - Platform to Future Affordable Sustainable Therapies.
PharmaNL is kicking off with €80 million in funding from the National Growth Fund to invest in research facilities and human capital.
Source: PharmaNL
Vandaag is bekend gemaakt dat ZonMw verwacht in september een nieuwe subsidieoproep binnen de PharmaNL Shared Development Infrastructure (SDI)-programmalijn te openen.
What if a surgeon could tell within five minutes whether a tumour has been completely removed? That is exactly what LIFE Cooperative member SPCTR is working on. In the Groninger Ondernemers Courant, the SPCTR team talks about their groundbreaking technology, which will allow surgeons to see within five minutes whether a tumour has been completely removed.
Following the keynote by Peter Wennink, the conversation continues with a panel discussion in which we will explore the themes from the keynote in further depth and look at the issues from different perspectives.
